Since their introduction in 1959, development of hormonal contraceptives has beenongoing, with the ultimate aim of creating not only an effective and safe contraceptive method,but also a drug able to meet the need for treatment of other conditions, such as acne, seborrhea,and hirsutism, with few or no side effects. With this objective, a new progestin, chlormadinoneacetate (CMA), has been developed as a derivative of progesterone for contraception.Thisnew molecule has been introduced in combination with ethinylestradiol (EE) 30 μg as a safecontraceptivewith antiandrogenic properties. Many clinical studies have investigated this neworal combination and found it to be safe, with a Pearl Index similar to that of other combinedhormonal contraceptives. CMA, because of its antiandrogenic properties, has been also consideredeffective for resolution of acne, seborrhea, and hirsutism. The data show it to be asafe molecule in terms of glucose and lipid metabolism. No major weight changes have beenlinked with its use, and it seems to be the only progestin able to reduce fat mass during use.The CMA-EE combination is well tolerated and acceptable to women. Adverse events relatedto its use are similar to those reported with other third-generation contraceptives.We canconclude that CMA-EE is an effective, safe, and well tolerated antiandrogenichormonalcontraceptive.
